各领域专家汇聚在BioSpark Monthly News论坛，交流过去一个月发生的生物医药领域大事件。
本月热点
TOPICS
Sana announces positive clinical results from type 1 diabetes study of islet cell transplantation without immunosuppression;
After Novo Nordisk and Biogen, AbbVie became San Diego biotech Neomorph’s third partner in developing molecular glues；
JNJ’s Amivantamab plus Lazertinib showed statistically significant and clinically meaningful OS improvement vs. Osimertinib in 1L locally advanced or metastatic NSCLC with EGFR mutations；
Eli Lilly acquired Scorpion’s mutant-selective PI3Ka inhibitor program for $2.5B;
IGM Biosciences halted development of 2 bispecific T cell engagers for autoimmune diseases;
Akero Therapeutics reported positive phase 2b results of bivalent FGF21 analog Efruxifermin in MASH patients with biopsy-confirmed compensated cirrhosis;
JNJ acquired Intra-Cellular for $14.6B to double down on neurological diseases;
Vigil Neuroscience's TREM2-targeted VG-3927 showed early promise in phase 1 Alzheimer's trial, moving on to phase 2；
Neumora’s Navacaprant failed the first of three major depression phase 3 trials.
活动详情
主题：Monthly biotech news discussion - January 2025 in review
时间：2025年2月1日 Sat 8:00 PM（EST）/ 2025年2月2日 周日 早上9:00 AM（北京时间）
地点：zoom meeting（扫描二维码获得zoom注册链接或点击文末“阅读原文”）
嘉宾：
Jimmy Wang (王俊), Assistant Professor @ New York University
(https://www.linkedin.com/in/jun-jimmy-wang-69a16a58/)
Ethan Xu (徐亦迅), VP of Bioinformatics @ Aspen Neuroscience
(http://linkedin.com/in/ethan-yixun-xu-2b915a4)
Haoran Wang(王浩然), CEO @ Neoland Biosciences Co.,Ltd.
(https://www.linkedin.com/in/hao-ran-wang-228648b)
Yanran He (何嫣然), Investment Director @ Sinopharm-CICC
(https://www.linkedin.cn/injobs/in/yanranhe)
Leon 'Jun' TANG (唐钧), Founding Partner @ InScienceWeTrust BioAdvisory
(https://www.linkedin.com/in/leontangnyc/)
Ashley Buckle, Chief Technology Officer & Co-Founder @ Stealth Mode Biotech
(https://www.linkedin.com/in/ashleybuckle/)
Sean Yao(姚翔),Co-Founder of Insilico Biosystems
(https://www.linkedin.com/in/xyao2011)
Hong Yue(岳宏),Researcher @ Dana-Farber Cancer Insitute / Harvard medical school
(https://www.linkedin.com/in/hong-yue-56392282/)
Avery Yan (晏庆红), Founder & CEO @ Riboway Therapeutics
(https://www.linkedin.com/in/avery-yan/)
Wenjun Wu (Armstrong, 吴文君), Director @ HanKang Venture
(https://www.linkedin.com/in/文君-吴-14787b95/)
本期活动组织：Ethan Xu
本月热点总结：Armstrong和monthly news嘉宾
活动直播伙伴
About us
BioSpark
BioSpark Group成立于2019年8月，是在美国麻省注册的非盈利机构。BioSpark致力于推动生命科学领域的高级人才交流，建立富有合作和互助精神的社群生态环境，实现学术和企业的跨界交流及思想碰撞，从而帮助华人科学家在世界生物医药领域提升领导力、开拓企业家精神及促进科学发现的商业转化。
BioSpark Group is a non-profit corporation registered in Massachusetts of the United States. The purpose of BioSpark Group is to establish a biotechnology ecosystem with a collaborative and supportive scholar network, promote leadership and entrepreneurship, and facilitate scientific translation.
成为BioSpark会员：BioSpark期待您的加入--会员推荐与申请
Follow us on Twitter:
https://twitter.com/BioSpark_Group
Follow us on LinkedIn:
https://www.linkedin.com/company/biospark-group
Email us: info@BioSpark.org
合作或加入日常活动交流群，请添加小助手微信号：BioSpark-Group
